الولايات المتحدة · منصات وبيانات · MarketBeat

Oruka’s ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study

نشره MarketBeat · الولايات المتحدة منذ 2 س

Oruka Therapeutics (NASDAQ:ORKA) reported interim week 16 results from EVERLAST-B, a Phase IIb dose-ranging study of ORKA-001 in adults with moderate-to-severe plaque psoriasis.…

اقرأ المقال كاملًا على MarketBeat سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (www.marketbeat.com)

يستحق القراءة أيضًا

The Motley Fool

Is a Stock Market Crash Coming? What History Says a $10,000 Investment in an S&P 500 ETF Could Be Worth at the End of 2027.

Seeking Alpha

Brixmor Property raises dividend by 7.3% to $0.33 a share

Investing.com

MSCI general counsel Robert Gutowski sells $1.48M in stock

MarketWatch

What gave this city its ‘best place to retire’ crown? You can actually afford to live there.

TheStreet

Banks are locking AI agents out, Hashgraph CIO Gregg Bell says blockchain is the way back in

Benzinga